Iovance wins Australian approval for Amtagvi in advanced melanoma, third global market

Filed June 10, 2026 · Period ending June 4, 2026 · ~1 min read

Key Changes

• high

  Australia's TGA approved Amtagvi for previously treated advanced melanoma, marking the third global market authorization and first solid tumor T cell therapy in Australia, a country with the world's highest melanoma rate (17,000 new cases annually).

  Exhibit 99.1 verify on EDGAR →
• high

  Shareholders approved increasing authorized common stock by 150M shares (from 500M to 650M), passing with 77.4% support and 21.7% opposition, providing equity capacity for future capital raises or acquisitions without immediate dilution.

  Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
• high

  Company is establishing its first Australian treatment center as part of international expansion strategy targeting high-melanoma-prevalence markets, critical for generating revenue outside the U.S.

  Exhibit 99.1 verify on EDGAR →